Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Immunemed Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to a distinct examiner and a distinct art unit. The company's current prosecution profile is characterized by this single active matter within the patent office. This concentrated focus suggests that the company's current intellectual property efforts are directed toward a specific technical innovation within the biotechnology sector.
STONEBRAKER, ALYSSA RAE is the busiest examiner for the portfolio, managing 1 pending office action. This figure matches the total of pending office actions for the company. The involvement of a distinct examiner and a distinct art unit shows that the current workload is not distributed across multiple personnel or administrative divisions. This singular point of contact simplifies the administrative tracking of the company's patent applications.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STONEBRAKER, ALYSSA RAE | 1 | 58.9% | +49.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18686099 | ANTIBODY DRUG FOR PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASES | STONEBRAKER, ALYSSA RAE | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18686099 | ANTIBODY DRUG FOR PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASES | STONEBRAKER, ALYSSA RAE | 1642 | §102§103§112DP | Non-Final OA | — | Pending | Feb 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialImmunemed Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alyssa Rae Stonebraker has the most, with 1 of Immunemed Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
